Blog

Continue Reading

  • ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study – UroToday

    1. ESMO 2025: Perioperative Enfortumab Vedotin (EV) plus Pembrolizumab (Pembro) in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study  UroToday
    2. Pfizer and Astellas announce positive results from phase 3ev-303 clinical trial for Padcev in combination with Keytruda  TradingView
    3. Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal  The American Journal of Managed Care® (AJMC®)
    4. ESMO25: Padcev, Keytruda regimen given before, after surgery shines in bladder cancer  FirstWord Pharma
    5. KEYNOTE-905: EV/pembrolizumab emerges as new option for cisplatin-ineligible MIBC  Urology Times

    Continue Reading

  • NHS to roll out first long-acting injection to prevent HIV

    NHS to roll out first long-acting injection to prevent HIV

    17 October 2025 — Around 1,000 people at risk of HIV will be offered a new long-acting injection on the NHS if they cannot have pills to protect them from the virus.

    The rollout of this preventative therapy takes NHS England one step closer to…

    Continue Reading